PICTOR


Associated tags: COVID-19, Health, Pictor, Vaccine, Infection, Other Health, Medical Supplies, ELISA, Infectious Diseases, Pharmaceutical industry, Patient, General Health, Medical Devices, Vaccination, Severe acute respiratory syndrome coronavirus 2, MD, NP, SP, Antibody, Pharmaceutical

Pictor announces funding round after successful launch in New Zealand and USA of SARS-CoV-2 Antibody Test

Retrieved on: 
Sunday, December 4, 2022
COVID-19, Medical Devices, Medical Supplies, Infectious Diseases, Other Health, Health, General Health, Agriculture, Natural Resources, Lazarus, Animal Health, ELISA, Health, Acceleration, Morrison, Infection, Patient, Ministry, Disease, COVID-19, Growth, H. R. L. Morrison & Co, Renewable energy, Pharmaceutical industry, Vaccine, Pictor, MD

This follows the recent successful launch of the PictArray SARS-CoV-2 IgG Antibody Test through Rako Science in New Zealand and key partners in the US.

Key Points: 
  • This follows the recent successful launch of the PictArray SARS-CoV-2 IgG Antibody Test through Rako Science in New Zealand and key partners in the US.
  • The test better informs patients and doctors in determining whether the patient should be immunized or boosted, said Pictors Chief Medical Officer Tadd Lazarus, MD.
  • Pictor has also leveraged its multiplex platform to develop an Animal Health business and is poised to launch two tests in Q2, 2023.
  • Former Morrison & Co. CEO Marko Bogoievski is helping lead the current funding round following his investment and involvement in Pictor since early 2022.

Pictor and Rako Science bring improved access to COVID-19 antibody testing for New Zealand with technology from Tasso

Retrieved on: 
Thursday, November 24, 2022
Data Management, Technology, Managed Care, Other Health, Health, General Health, Security, Health Technology, Other Science, Science, COVID-19, Patient, University, Risk, Infection, Vaccination, ELISA, Public health, COVID-19, IANZ, Severe acute respiratory syndrome coronavirus 2, Investment, Saliva, Science, Engineering, NP, PCR, Brooks, Canterbury, Antibody, SP, Vaccine, Medicine, Pharmaceutical industry, Pictor

Rako Science will utilize its national network by collecting blood samples with a device from Tasso, Inc., and undertake testing for COVID-19 antibodies.

Key Points: 
  • Rako Science will utilize its national network by collecting blood samples with a device from Tasso, Inc., and undertake testing for COVID-19 antibodies.
  • In an effort to protect the entire New Zealand population as much as possible, Pictor has partnered with Rako Science and Tasso to improve accessibility.
  • Pictor partnered with Rako Science, an Auckland-based high-tech pathology company and U.S.-based Tasso, Inc., the leading provider of convenient, clinical-grade blood collection solutions.
  • This test plays to one of our core strengths which is rapid, translational science, said Leon Grice of Rako Science.

Pictor Receives CE Mark for its PictArray™ SARS-CoV-2 Antibody Test, Indicating Whether Patients Require COVID-19 Booster

Retrieved on: 
Wednesday, June 22, 2022
Medical Supplies, Health, Infectious Diseases, Other Health, Pharmaceutical, Biotechnology, Lazarus, Antibody, Diagnosis, Urban economics, Public health, Infection, COVID-19, Public health emergency, World, CE, IVDD, NZD, CEO, CE marking, European Economic Area, Vaccination, ANZ, Severe acute respiratory syndrome coronavirus 2, ELISA, World Health Organization, Twitter, Patient, NP, SP, Public Health Emergency of International Concern, Vaccine, Pictor, MD

The CE Mark will allow the company to market its COVID-19 antibody test in Europe and gain regulatory approval in Southeast Asia.

Key Points: 
  • The CE Mark will allow the company to market its COVID-19 antibody test in Europe and gain regulatory approval in Southeast Asia.
  • Receiving CE registration enables Pictor to establish a footprint with partner laboratories and research bodies within Europe which is an important market for us, said Howard Moore, CEO of Pictor.
  • It will also indicate whether at-risk patients have failed to mount a detectable antibody response despite vaccination or infection (SP and NP negative).
  • The companys lead product, PictArray SARS-CoV-2 IgG ELISA Kit, enables more informed clinical intervention to manage the threat of COVID-19.

Biotech Firm Tackling COVID-19 and M. bovis Announces Successful Development of Rapid, Accurate Johne’s Disease Assay

Retrieved on: 
Monday, June 13, 2022
Other Health, General Health, Pharmaceutical, Other Natural Resources, Medical Devices, Infectious Diseases, Natural Resources, University, Education, COVID-19, Biotechnology, Medical Supplies, Health, PCT, Biomarker, Infection, Time, Transport, Associate, Animal, Pictor, Massey University, Disease, School, Ministry, Development, Risk, Technology, COVID-19, MAP, Twitter, Mycobacterium avium subsp. paratuberculosis, Disease management, Environment, Education, ELISA, Research and development, Pharmaceutical industry, Vaccine, Agriculture, Research

The PictArray multiplex enzyme-linked immunosorbent assay (ELISA) technology allows multiple biomarkers to be tested in a single well.

Key Points: 
  • The PictArray multiplex enzyme-linked immunosorbent assay (ELISA) technology allows multiple biomarkers to be tested in a single well.
  • This feature increases the information gained by the clinical testing laboratory, enabling improved disease management on the farm.
  • Earlier detection of Johnes disease would allow infected animals to be removed from herds sooner, minimizing transmission.
  • The companys lead product, PictArray SARS-CoV-2 IgG ELISA Kit, enables more informed clinical intervention to manage the threat of COVID-19.

Bolstered By Investment, Pictor Partners with Mobility Health to Offer PictArray™ SARS-CoV-2 Antibody Test, Indicating Whether Patients Require COVID-19 Booster

Retrieved on: 
Wednesday, April 13, 2022
Biotechnology, Pharmaceutical, Medical Supplies, General Health, Health, Medical Devices, Infectious Diseases, Other Health, Lazarus, Public Health Emergency of International Concern, CEO, The Warehouse Group, Gaps, Warehouse, Culture, COVID-19, NZD, Twitter, Software, Public health emergency, Research, NP, Leadership, Morrison, Deen Dayal Mobile Health Clinic, World, Infection, Patient, Growth, Vaccination, Vaccine, H. R. L. Morrison & Co, SP, Mobility, Antibody, Partnership, World Health Organization, Severe acute respiratory syndrome coronavirus 2, Accreditation, University, Pharmaceutical industry, Renewable energy, MD, Pictor

It will also indicate whether at-risk patients have failed to mount a detectable antibody response despite vaccination or infection (SP and NP negative).

Key Points: 
  • It will also indicate whether at-risk patients have failed to mount a detectable antibody response despite vaccination or infection (SP and NP negative).
  • The PictArray SARS-CoV-2 Antibody Test is a high performance, all-in-one, NP/SP COVID-19 antibody test with serological differentiation.
  • Pictor is pleased to partner with Mobility Health to offer such a unique and important test, said Howard Moore, CEO of Pictor.
  • Mobility Health is a member of the Mason, Ohio living lab initiative to scale biohealth start-up companies.. More information can be found at www.mobilityhealthlab.com .